




MEDICINAL PRODUCTS 2018

Oncocyte Corp
Rank 42 of 49





MEDICINAL PRODUCTS 2018

Oncocyte Corp
Rank 42 of 49



The relative strengths and weaknesses of Oncocyte Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncocyte Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Oncocyte Corp is the variable Net Income, reducing the Economic Capital Ratio by 176% points.

The company's Economic Capital Ratio, given in the ranking table, is -197%, being 175% points below the market average of -22%.

Input Variable	Value in 1000 USD
Assets, Current	8,528
Assets, Non-Current	0
General and Administrative Expense	11,675
Goodwill	746
Liabilities, Current	4,454
Liabilities, Non-Current	0
Other Assets	120
Other Compr. Net Income	-234
Other Expenses	0
Other Liabilities	1,359
Other Net Income	-526
Other Revenues	0
Property, Plant and Equipment, Net	822
Research and Development	7,174

Output Variable	Value in 1000 USD
Liabilities	5,813
Assets	10,216
Expenses	18,849
Revenues	0
Stockholders Equity	4,403
Net Income	-19,375
Comprehensive Net Income	-19,492
Economic Capital Ratio	-197%